• health

• news

There is also a Chinese vaccine for corona, what do we know about it?

The Chinese Sinovac vaccine has not yet released the results of the third and most important phase of its clinical trial, but despite this its doses have already been sold to other countries.

How effective is it and what is its price?

Tags

• Vaccine for corona

• China

• Corona

• covid-19

Walla!

health

Thursday, 10 December 2020, 12:33

• Share on Facebook

• Share on WhatsApp

• Share on general

• Share on general

• Share on Twitter

• Share on Email

0 comments

• Bizarre documentation on the baby's intercom camera

• Viral video of a zoom call

• Head of Public Health Services: "This is the beginning of a wave ...

• Laura from this

• Roldin Donut Collection, Hanukkah 2020

• Britain approves the use of the Pfizer vaccine for Corona ...

• Abdominal exercises by fitness trainer Or German

• Corona vaccination campaign in the UK launched: 90-year-old grandmother ...

• Nissenkorn: Advance legalization of cannabis within nine ...

• 400,000 high school students return to school for fear ...

• After 3 months: Middle school students return home ...

• Anger in Japan after dozens of American soldiers became infected ...

In the video: The first vaccines for Corona arrived in Israel (Photo: GPO)

The vaccine discourse in Israel and around the world focuses on three main vaccines today: the Modern vaccine, the Pfizer vaccine and the Astra-Zenka vaccine.

But there are other vaccines, such as the developed Sputnik V in Russia and the Israeli one developed at the Biological Institute, about which we have also heard little.

This discourse has recently lacked another vaccine - the Chinese vaccine from the Sinovac company.

Deliveries of the Coronavac vaccine, developed by the Chinese pharmaceutical company Sinovac, have just recently landed on Indonesian soil in preparation for the planned mass vaccination operation there.

And an additional shipment of 1.8 million additional vaccine doses is expected to arrive from China to Indonesia during the month of January.

However, this vaccine has not yet completed the final stage of its clinical trial, which begs the question: what do we even know about the Chinese vaccine?

More on Walla!

NEWS

You asked, the expert answers: everything that is important to know about corona vaccines

To the full article

CoronaVac is a killed vaccine that uses inactive parts of the corona virus to stimulate the body's immune response, without the risk of developing a serious disease response.

This is in contrast to the vaccines of Pfizer and Moderna, which use their vaccines with mRNA technology which means that parts of the genetic code of the virus are injected into the body, causing the body to start producing viral proteins but not the virus as a whole, which triggers an immune response.

Vaccination with more traditional technology, unlike modern and Pfizer mRNA vaccines.

Researcher holds a syringe with a Coronavac vaccine from the Chinese company Sinovac (Photo: AP)

"CoronaVac is a more traditional vaccine, which is used in very common and well-known vaccines, such as the rabies vaccine," said Prof. Lu Dahai, of Nanyang University of Technology, in an interview with the BBC.

"MRNA vaccines are newer vaccines, and to this day no known example of them is a successful example in a population vaccine," he added.

On paper, the Chinese vaccine already has a distinct advantage over its competitors from Moderna and Pfizer and is that it can be stored and transported in regular refrigerators and at a standard cooling temperature of between 8 and 2 degrees Celsius.

This is similar to the Oxford and Astra-Zenka vaccine, although it is based on a genetically modified cold virus taken from chimpanzees, so that is where the similarity between these two vaccines ends.

What is the effectiveness of the Chinese vaccine?

At this stage, it is difficult to determine exactly what the level of effectiveness of Sinovac's vaccine is.

The scientific journal The Lancet has so far published only official results from the first and second phase of the clinical trial, and not from the more crucial and extensive third phase.

Zhu Fengchai, one of the authors of the article published in the journal, said that these results, based on the first phase in which there were 144 experimenters, and the second in which 600 experimenters participated, indicate that the Chinese vaccine "is suitable for emergency approval".

More on Walla!

NEWS

• A viral image shows how cruel the reality of the corona in the US is

• Towards a third closure: This is what two weeks at home do to the body

• 5 protein-rich nuts that are worth adding to the menu

• The perfect time to get ready for next summer: the gel that raises the stretch marks

In September, a source from Sinovac said that the vaccine had been tested on a thousand experimenters and that among them "only a few had experienced side effects of mild fatigue or some discomfort ... no more than 5%."

In October, the third and most extensive phase of the trial of the Chinese vaccine began, in Brazil - where the death toll from Corona is the second highest in the world.

In November the experiment was briefly suspended due to a report of the death of one of the experimenters, however it was quickly renewed after it became clear that the experimenter's death was not related to the vaccine he received.

The Botanic Institute in Brazil, which is Sinovac's partner body for the third phase of the experiment, said it expects the company to publish the results of the final phase of the experiment by December 15.

The first shipment of Corona vaccines from the Chinese company Sinovac lands in Indonesia (Photo: AP)

"Based on data from the early stages of the trial, CoronaVac appears to be an effective vaccine. But we must wait and see the final results from the third phase of the trial," said Professor Lou Dahai.

"The third stage is the one conducted on thousands of experimenters, with a control group receiving a placebo, adhering to random and blind methods (in which almost no one in the experiment knew which of the experimenters received the real vaccine and which the dummy). And this is the only way to determine For use at the general population level, "he added.

Coronavac is not the only vaccine developed in China, even the Chinese government-owned Chinese company Sinofarm has a vaccine against Corona and yesterday (Wednesday) the UAE announced that it was found to be 86% effective in an experiment conducted by Abu Dhabi.

However, the announcement included very few details about the experiment, and was only reported to have started in September and included 31,000 volunteers aged 18-60 from 125 different countries.

What is the production capacity of Sinovac?

Its state-of-the-art 20,000-square-foot Sinovac plant will produce about 300 million vaccine doses a year, the company chairman told the media. Like the other vaccines developed against Corona, the Chinese vaccine requires two doses. This means the company can vaccinate. 150 million people a year. This is quite a bit, but it is a little over a tenth of China's population.

However, the company has already supplied rations to other countries such as Indonesia, and has signed deals with other countries, including: Brazil, Turkey and Chile. Infing has previously pledged $ 2 billion to supply vaccines to the African continent and has even offered South American and Caribbean countries a $ 1 billion loan to purchase vaccines for their citizens.

How much does it cost?

Here, too, the details are unclear and unequivocal. One report in China spoke of an order of magnitude of about $ 30 for one vaccine dose, while according to the state-owned pharmaceutical company Bio-Pharma in Indonesia, it estimated the cost of a vaccine dose at about $ 13.60. This is a significantly higher cost than the Oxford and AstraZenica fat vaccine, which is valued at $ 4, but lower than the modern vaccine (about $ 33 per dose).

• Share on Facebook

• Share on WhatsApp

• Share on general

• Share on general

• Share on Twitter

• Share on Email

0 comments